Skip to content

Press Release · Press Releases · Asia-Pacific

Samsung Biologics Achieves 'Negligible Risk' Rating in Sustainalytics ESG Assessment

Issued by PR Newswire

Image: PR Newswire

Earns ESG Risk Rating score of 9.0, ranking among the top 0.5% in the pharmaceuticals industry Advances from 'Low Risk' to 'Negligible Risk,' the lowest ESG risk category Recognition reflects continued improvements in ESG risk management across operations INCHEON, South Korea, Nov. 3,...

This press release summary is reproduced from the issuer's public feed.

Read the full release at PR Newswire

Original publisher: PR Newswire

Spotted an error? Request a correction · Corrections Policy

Related stories

Press Release

Sempra Reports Strong Third-Quarter 2026 Results

Advancing 2026 Value Creation Initiatives Updating 2026 GAAP EPS guidance range Guiding to high-end of 2026 adjusted EPS guidance range Announcing expected 20% increase to Oncor's base capital plan SAN DIEGO, Nov. 5, 2026 /PRNewswire/ -- Sempra (NYSE: SRE) today reported third-quarter...

PR Newswire ·